Mirabegron

Overview

Mirabegron (formerly YM-178, trade name Myrbetriq) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012. Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cardiovascular and blood system | Adrenergic Receptor

Product Information

• Catalog No.: B0084-182334
• CAS No.: 223673-61-8
• Molecular Formula: C21H24N4O2S
• Molecular Weight: 396.51
• Purity: 98%
• Storage: Store in a tightly closed container , in a cool and dry place.

Source

Original product source